Jun 2026 (Q2 FY26) — Aug 6, 2026
Halozyme Q2 FY26 — Record Royalty Growth and New Deal Momentum
Read the full callHalozyme (HALO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Halozyme earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 481 | +47.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 59.8 | −2.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 230 | +39.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$122.5 +0.54% · +$0.66
Performance +82.8% 1Y
1Y: $67.03 on 17 Oct 2025 → $122.5. High $122.5 (19 Oct 2026), low $61.63 (27 Mar 2026).
- Previous close
- $121.84
- 52-week range
- $61.63 – $122.5
- One year
- +84.29%
Overview
- Symbol
- HALO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 11, 2026
Halozyme Q1 FY26 — Strong Royalty Growth and Reaffirmed Guidance, New Buyback Program
Read the full callEvery analysed call
Halozyme earnings calls (HALO)
Financials
What the filings say
Net profit, year on year: +39% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 290 | 298 | 265 | 326 | 354 | 452 | 377 | 481 |
| Expenses | 127 | 123 | 123 | 123 | 136 | 545 | 192 | 193 |
| Operating profit | 163 | 176 | 142 | 202 | 218 | -93 | 185 | 288 |
| Operating margin | 56.3% | 58.9% | 53.4% | 62.1% | 61.5% | −20.6% | 49.0% | 59.8% |
| Interest | 5 | 5 | 5 | 4 | 4 | 5 | 6 | 6 |
| Profit before tax | 165 | 178 | 144 | 205 | 219 | -101 | 180 | 285 |
| Tax rate | 17.0% | 23.1% | 17.9% | 19.4% | 20.0% | −40.4% | 16.8% | 19.3% |
| Net profit | 137 | 137 | 118 | 165 | 175 | -142 | 150 | 230 |
| EPS ($ per share) | 1.08 | — | 0.96 | 1.36 | 1.49 | — | 1.27 | 1.96 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -531 | -604 | -475 | -59 | 143 | 91 | 360 | 55 |
| Total liabilities | 191 | 474 | 429 | 907 | 1,672 | 1,649 | 1,700 | 2,477 |
| Fixed assets | 7 | 11 | 7 | 7 | 35 | 38 | 41 | 44 |
| Total assets | 440 | 566 | 580 | 1,104 | 1,842 | 1,733 | 2,063 | 2,525 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -49 | -85 | 55 | 299 | 240 | 389 | 479 | 652 |
| Cash from investing | 2 | -6 | 78 | -406 | -487 | -97 | -263 | -546 |
| Cash from financing | -64 | 153 | -106 | 78 | 362 | -408 | -219 | -85 |
| Net cash flow | -111 | 62 | 28 | -29 | 115 | -116 | -3 | 21 |
| Capital expenditure | -5 | -4 | -3 | -1 | -5 | -15 | -11 | -7 |
| Free cash flow | -54 | -89 | 53 | 298 | 235 | 373 | 468 | 645 |
HALO revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Royalty | 53% | 57% | 64% | 63% | — | — | 64% | 64% | +49.6% |
| Product | 30% | 27% | 29% | 25% | 27% | 27% | 35% | 27% | +59.0% |
| Bulk R Hu PH 20 | — | — | — | — | — | — | 20% | 12% | — |
| Proprietary Products Sales | 14% | 16% | 14% | 14% | 15% | 13% | 11% | 12% | +19.3% |
| Collaborative Agreements | 17% | 16% | 7% | 12% | 7% | 16% | 1% | 9% | +13.2% |
| Upfront Fees | — | — | — | 0% | 0% | — | 0% | 7% | — |
| Device Partnered Products | 5% | 4% | 6% | 4% | 3% | 3% | 4% | 3% | +23.7% |
| Event Based Development and Regulatory Milestone and Other Fees | 6% | 5% | 0% | 8% | 0% | 5% | — | 1% | -76.7% |
| Device Licensing and Development | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | -39.4% |
| Sales Based Milestone | — | — | 6% | 3% | 6% | — | 0% | 0% | -100.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
185 filings between Nov 1, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$48.38M
106 sales by 5 insiders
96% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 9
- Award — granted as compensation
- 51
- Option exercise — converted options into shares
- 18
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Torley Helen | — | $42.15M | Oct 8, 2026 |
| Posard Matthew L. | — | $2.61M | Oct 1, 2026 |
| Caudill Cortney | — | $2.23M | Mar 10, 2026 |
| Connaughton Bernadette | — | $839.4K | Aug 10, 2026 |
| Krishnan Mahesh | — | $547.8K | Jun 29, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 3,090 | $336.5K |
| Oct 8, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 11,900 | $1.31M |
| Oct 8, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 4,810 | $520.3K |
| Oct 8, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Oct 8, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 200 | $22.1K |
| Oct 7, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 200 | $22.7K |
| Oct 7, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 900 | $101.5K |
| Oct 7, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 8,600 | $954.9K |
| Oct 7, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 10,300 | $1.15M |
| Oct 7, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Oct 6, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 2,300 | $248.2K |
| Oct 6, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Oct 6, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 6,000 | $656.0K |
| Oct 6, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 9,920 | $1.09M |
| Oct 6, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 1,780 | $197.2K |
| Oct 1, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 1,100 | $120.5K |
| Oct 1, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 100 | $11.0K |
| Oct 1, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 730 | $78.2K |
| Oct 1, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 3,300 | $357.9K |
| Oct 1, 2026 | Daly James M Director | Award | 1,169 | $0 |
| Sep 16, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 8,896 | $961.1K |
| Sep 16, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 3,000 | $320.5K |
| Sep 16, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 3,100 | $329.0K |
| Sep 16, 2026 | Posard Matthew L. Director | Sale 10b5-1 plan | 4,000 | $436.0K |
| Sep 11, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 4,508 | $484.8K |
| Sep 11, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 15,492 | $1.66M |
| Sep 11, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Sep 10, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 5,412 | $582.2K |
| Sep 10, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 14,588 | $1.56M |
| Sep 10, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Sep 9, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 6,596 | $711.2K |
| Sep 9, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 13,304 | $1.43M |
| Sep 9, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 100 | $10.9K |
| Sep 9, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Sep 1, 2026 | Appelhans Dannielle Director | Award | 1,161 | $0 |
| Aug 19, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 3,200 | $344.8K |
| Aug 19, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 9,600 | $1.03M |
| Aug 19, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 7,200 | $765.8K |
| Aug 19, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Aug 18, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Aug 18, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 9,400 | $985.8K |
| Aug 18, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 4,897 | $509.8K |
| Aug 18, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 5,703 | $587.9K |
| Aug 17, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 2,100 | $213.7K |
| Aug 17, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 500 | $50.2K |
| Aug 17, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 900 | $89.1K |
| Aug 17, 2026 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 plan | 20,000 | $368.2K |
| Aug 17, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 9,000 | $923.0K |
| Aug 17, 2026 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 plan | 7,500 | $776.1K |
| Aug 10, 2026 | Connaughton Bernadette Director | Sale 10b5-1 plan | 1,626 | $167.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HALOZYME THERAPEUTICS, INC.
Free account. Everything above stays public.
Write why you follow HALOZYME THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading